4.5 Article

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Long term pharmacotherapy for obesity and overweight: updated meta-analysis

Diana Rucker et al.

BMJ-BRITISH MEDICAL JOURNAL (2007)

Article Medicine, General & Internal

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

JP Despres et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Medicine, General & Internal

Meta-analysis: Pharmacologic treatment of obesity

ZP Li et al.

ANNALS OF INTERNAL MEDICINE (2005)

Article Health Care Sciences & Services

The PHQ-9 - Validity of a brief depression severity measure

K Kroenke et al.

JOURNAL OF GENERAL INTERNAL MEDICINE (2001)

Article Endocrinology & Metabolism

Development of a brief measure to assess quality of life in obesity

RL Kolotkin et al.

OBESITY RESEARCH (2001)

Article Endocrinology & Metabolism

Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans

A Katz et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)